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Abstract
 Background & Aims—Inhibitors of tumor necrosis factor (anti-TNF agents) are the most 
effective therapy for Crohn’s disease (CD). We evaluated the real-world comparative effectiveness 
and safety of different anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) in 
biologic-naïve patients with CD in a retrospective, propensity-matched cohort study using a 
national administrative claims database (Optum Labs Data Warehouse).
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 Methods—We identified 3205 biologic-naïve CD patients (mean age, 41±15 years; 45% male; 
median follow-up period after anti-TNF therapy, 19 months; 44.5% on infliximab and 38.9% on 
adalimumab) who received their first prescription for an anti-TNF agent (infliximab, adalimumab, 
or certolizumab pegol) after a 12-month period without any anti-TNF treatment (baseline), and 
with a minimum follow-up period of 6-months after their initial anti-TNF prescription, between 
2006 and 2014. The primary outcomes were all-cause and CD-related hospitalization, abdominal 
surgery, corticosteroid use, and serious infections. We performed a propensity-matched, Cox 
proportional hazard analysis, accounting for baseline demographics, healthcare utilization, 
comorbidities, and use of CD-related medication.
 Results—Compared to adalimumab-treated patients, infliximab-treated patients had a lower 
risk of CD-related hospitalization (adjusted hazard ratio [aHR], 0.80; 95% confidence interval 
[CI], 0.66–0.98), abdominal surgery (aHR, 0.76; 95% CI, 0.58–0.99), and corticosteroid use (aHR, 
0.85; 95% CI, 0.75–0.96). Compared to certolizumab pegol-treated patients, infliximab-treated 
patients had a lower risk of all-cause hospitalization (aHR, 0.70; 95% CI, 0.52–0.95) and CD-
related hospitalization (aHR, 0.59; 95% CI, 0.39–0.90). Adalimumab-treated patients had 
outcomes comparable to those of certolizumab pegol-treated patients. All agents had comparable 
risk of serious infections.
 Conclusion—In a retrospective analysis of a large cohort of biologic-naïve patients with CD, 
we found infliximab to be superior to adalimumab and certolizumab pegol for patient-relevant 
outcomes, without increased risk of serious infections.
Keywords
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 INTRODUCTION
Biologic therapy with anti-tumor necrosis factor-α (anti-TNF) agents such as infliximab 
(IFX), adalimumab (ADA) and certolizumab pegol (CZP), alone or in combination with 
immunomodulators, is currently the most effective treatment in inducing and maintaining 
clinical remission in patients with CD, and has been shown to decrease risk of 
hospitalization and surgery.1–7 In the absence of head-to-head trials, there is a significant 
unmet need among patients and clinicians to understand the relative effectiveness and safety 
of different anti-TNF medications. Current decisions on the choice of anti-TNF agent are 
primarily driven by insurance coverage and patient and physician preferences. There are 
differences in the molecular construct, dosing and route of administration of these agents, 
and in comparing CZP with ADA or IFX, subtle differences in mechanism of action, and 
hence, it is conceivable that there may be differences in efficacy.8
We sought to study the real-world comparative effectiveness and safety of different anti-TNF 
agents in biologic-naïve adult patients with CD, using a propensity-score matched 
retrospective cohort study, in a nationally representative administrative database of privately 
insured individuals derived from the Optum Labs Data Warehouse.9 Using patient-relevant 
outcomes of risk of all-cause and CD-related hospitalizations, abdominal surgery, need for 
corticosteroids, and risk of serious infections, the results of this study might assist 
Singh et al. Page 2
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
consumers, clinicians, purchasers, and policy makers to make informed decisions and 
potentially identify the need for additional clinical trial to improve the treatment of patients 
with IBD.
 METHODS
 Data Sources
We conducted a retrospective analysis of medical and pharmacy administrative claims from 
a large database, Optum Labs Data Warehouse, which includes privately insured and 
Medicare Advantage enrollees throughout the United States.9 The database contains data on 
more than 100 million enrollees, from geographically diverse regions across the United 
States, with greatest representation from the South and Midwest. Medical claims include 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
diagnosis codes; ICD-9 procedure codes; Current Procedural Terminology, Fourth Edition 
(CPT-4) procedure codes; Healthcare Common Procedure Coding System (HCPCS) 
procedure codes; site of service codes; and provider specialty codes. All study data were 
accessed using techniques compliant with the Health Insurance Portability and 
Accountability Act of 1996, and because this study involved analysis of preexisting de-
identified data, it was exempted from institutional review board approval.
 Study Population
We identified all patients who filled a prescription for an anti-TNF agent or received an 
infusion for an anti-TNF agent in the clinic setting between January 1, 2006 to June 30, 
2014. Our study cohort was comprised of adult patients (≥18 years of age) with: (a) at least 
one ICD-9 diagnosis code for CD (ICD 555.x) in the baseline period (prior to index date of 
anti-TNF prescription), either from an inpatient or outpatient visit, (b) continuous health 
plan enrollment with pharmacy benefits, with no anti-TNF prescription in the 12 months 
prior to index date (to identify a group of anti-TNF-naïve patients), and at least a 6-month 
minimum follow-up after index date. We excluded patients with a concomitant diagnosis of 
rheumatoid arthritis, ankylosing spondylitis, psoriasis or psoriatic arthritis, within the 
previous 12 months of anti-TNF prescription date, as competing causes for prescribing anti-
TNF agents. Figure 1 shows the flow of patients for identification of the cohort, and 
Supplementary Figure 1 outlines the general study scheme.
 Exposures and Outcomes of Interest
The primary exposures of interest were IFX, ADA or CZP prescription for CD. We 
considered patients as being continuously exposed from the index date (date of first 
prescription of anti-TNF agent) for the duration of their prescription. Patients were followed 
until occurrence of outcome of interest (see below), disenrollment from healthcare plan or 
completion of study (last date of follow-up, December 31, 2014) or discontinuation of index 
anti-TNF (absence of new prescription for a period of >4 months [for IFX] or >3 months 
[for ADA or CZP]).
The primary outcomes of interest were:
Effectiveness Outcomes
Singh et al. Page 3
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
a) All-cause hospitalization
b) CD-related hospitalization, with CD either as the primary diagnosis, 
or as a secondary diagnosis if the primary diagnosis was related to a 
gastrointestinal symptom (abdominal pain, diarrhea, nausea, 
vomiting, constipation, gastrointestinal bleeding)
c) CD-related surgery, including intestinal or perianal surgical 
procedure (identified using established procedural codes [available 
upon request])
d) Corticosteroid prescription, occurring at least 60 days after the start 
of anti-TNF therapy (to minimize confounding by disease severity)
e) Persistence on the index anti-TNF agent at 6-months (prescription 
of index anti-TNF agent between 140–220 days after index date) 
and 12-months (prescription of index anti-TNF agent between 325–
405 days after index date). Persistence on index anti-TNF agent at 
12m was assessed only in patients who were followed at least 12m 
after initiation of anti-TNF therapy.
Safety Outcomes
f) Hospitalization for serious or opportunistic infections as primary 
diagnosis (available upon request).
If the index anti-TNF agent was started during an inpatient hospitalization, then that 
hospitalization was not counted as an outcome; only inpatient admissions which were >23 
hours in duration were regarded as outcomes (to avoid misclassifying observation visits for 
IFX infusions as outcome).
 Covariates of Interest
Independent variables of interest included measures of healthcare utilization, comorbidities 
including surrogate markers of disease severity, and overall medication burden, including 
use of IBD-related medications, in the baseline period (prior to initiation of the index anti-
TNF agent) (Supplementary Appendix). Patients were classified as being on anti-TNF-based 
combination immunomodulator therapy if they received immunomodulator prescriptions 
within 30 days before and/or after anti-TNF index start date.
 Statistical Analysis
We examined the relative effectiveness of IFX, ADA and CZP on the risk of all-cause and 
CD-related hospitalization, abdominal surgery, corticosteroid use and serious infections, 
using two statistical approaches. First, our primary analysis was performed using 1:1 
propensity score matching without replacement to adjust for differences in baseline 
covariates.10 The matching was performed in three separate models for patients exposed to 
IFX (vs. ADA), IFX (vs. CZP) and CZP (vs. ADA). The propensity score model included 
demographic variables (age categories, sex, census region), date of initiation of index anti-
TNF, comorbidity index, healthcare utilization (as described above), surrogate markers of 
disease severity, medication class count, and IBD-related medications. We performed a 
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paired t-test for continuous variables, a McNemar test for dichotomous variables, and a 
Bowker’s test for categorical variables with more than two levels; then, we measured the 
standardized difference of each covariate in the propensity score model, and variables were 
considered to be different across treatment if after propensity score matching the 
standardized difference was greater than 10%. In order to correct for any remaining 
imbalance after the propensity score analysis was performed, we included remaining 
covariates that were shown to be different across treatment groups into the final multivariate 
Cox proportional hazard models for assessment of the outcomes of interest. Second, we 
performed an inverse probability-of-treatment weight (IPTW) analysis where the IPTW was 
applied to each observation in the Cox model in order to assess the relative effectiveness 
between IFX, ADA, and CZP. The IPTW analysis was derived by utilizing the propensity 
score on all observations before matching.11 In contrast to propensity-score matching in 
which the sample size usually decreases (as a result of matching), this type of modeling 
allowed us to retain all identified patients in the analysis, resulting in increased power.
We calculated hazard ratios (HR) with 95% confidence intervals (CI) for each outcome of 
interest separately, and patients were censored at time of treatment discontinuation or 
switching (to another anti-TNF agent), health plan disenrollment or end of observation 
period. We created the analytic dataset in SAS 9.3 and used Stata SE software (version 13.0) 
for statistical analysis.
We performed multiple sensitivity analyses to assess the robustness of our findings, as 
detailed in the Supplementary Appendix.
 RESULTS
 Characteristics of Patients
We identified 3205 biologic-naïve patients with CD, of whom 1427, 1248 and 530 patients 
were treated with IFX, ADA and CZP, respectively, as the index anti-TNF agent. Table 1 
describes the baseline demographic, clinical, treatment characteristics and healthcare 
utilization of the overall cohort and the three subgroups. Median follow-up after starting 
index anti-TNF agent was 19 months (interquartile range [IQR], 10–35). Only 6.3% of 
patients were >65 years old. Overall, the groups were comparable with regard to 
demographic, clinical variables, CD-related medication use and healthcare utilization in the 
baseline period. About 4.7% of patients had undergone an abdominal surgery in the 
preceding 12 months, with CZP-treated patients more likely to have undergone surgery 
(7.4%) as compared to ADA- (4.9%) or IFX-treated (3.7%) patients (p<0.001). The 
proportion of patients on anti-TNF-based combination therapy (immunomodulator 
prescriptions within 30 days before and/or after anti-TNF index start date) was higher in 
IFX-treated patients as compared to ADA- or CZP-treated patients (IFX vs. ADA vs. CZP: 
32% vs. 26% vs. 26%).
After propensity score matching, these groups were more balanced, with no significant 
difference in clinical variables, healthcare utilization or CD-related medication use 
(Supplementary Table 1A–C). Only a small number of variables fell outside a standardized 
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difference of 0.10 (Supplementary Figures 2A–C). These variables were additionally 
adjusted for in the propensity score-matched multivariable Cox proportional hazard analysis.
 Comparative effectiveness and safety of infliximab vs. adalimumab
A total of 1020 patients treated with IFX were propensity score-matched to 1020 ADA-
treated patients. On unadjusted analysis, the risks of all-cause and CD-related 
hospitalization, abdominal surgery and corticosteroid prescription were lower in IFX-treated 
patients compared to ADA-treated patients (Figure 2A–E). On Cox proportional hazard 
analysis, after additional adjustment for variables not balanced through propensity score 
matching, we observed that the risks of CD-related hospitalization (aHR, 0.81; 95% CI, 
0.66–1.00), abdominal surgery (aHR, 0.73; 95% CI, 0.56–0.97) and corticosteroid use >60 
days after initiation of anti-TNF therapy (aHR, 0.85; 95% CI, 0.75–0.96) were significantly 
lower in IFX-treated patients compared to ADA-treated patients (Table 2). Although the risk 
of all-cause hospitalization (aHR, 0.86; 95% CI, 0.74–1.01) was numerically lower in the 
IFX-treated patients, this was not statistically significant. The risk of serious infections 
requiring hospitalization was not significantly different in IFX- and ADA-treated patients 
(aHR, 0.88; 95% CI, 0.48–1.64). Persistence on index IFX and ADA was comparable at 6-
months (IFX vs. ADA, 78% vs. 78%, p=0.83) and 12-months (55% vs. 55%, p=0.79).
The overall results were similar on stratified analysis by anti-TNF monotherapy or 
concomitant immunomodulator therapy, although several of the results were not statistically 
significant in the latter strata likely due to loss of statistical power (Supplementary Table 2). 
On sensitivity analysis limiting only to patients with at least a 3-year baseline anti-TNF-free 
period, the overall summary estimates were comparable to the primary analysis for CD-
related hospitalization (aHR, 0.85), abdominal surgery (aHR, 0.75) and corticosteroid use 
(aHR, 0.87), although the results were not statistically significant (Table 2). The results were 
similar when restricting analysis to patients without inpatient hospitalization within 30 days 
prior to initiation of anti-TNF agents (Supplementary Table 3). The overall results were also 
comparable to the primary propensity-score matched analysis, when using inverse 
probability-of-treatment weight analysis (Supplementary Table 4).
 Comparative effectiveness and safety of infliximab vs. certolizumab pegol
A total of 253 patients treated with IFX were propensity-score matched to 253 CZP-treated 
patients. On unadjusted analysis, the risks of all-cause and CD-related hospitalization, 
abdominal surgery and corticosteroid prescription were lower in IFX-treated patients 
compared to CZP-treated patients (Figure 3A–E). On Cox proportional hazard analysis, we 
observed that the risks of all-cause and CD-related hospitalization were significantly lower 
in IFX-treated patients compared to CZP-treated patients (Table 2). Although the risks of 
abdominal surgery and corticosteroid prescription were numerically lower, these differences 
were not statistically significant. The risk of serious infections requiring hospitalization was 
not significantly different in IFX- and CZP-treated patients. Persistence on index IFX was 
higher compared to index CZP, both at 6-months (IFX vs. CZP, 78% vs. 70%, p=0.03) and 
12-months (53% vs. 42%, p=0.01).
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The overall results were similar in the stratified analysis by anti-TNF monotherapy or 
concomitant immunomodulator therapy (Supplementary Table 2). On sensitivity analysis 
limiting only to patients with at least a 3-year baseline anti-TNF-free period, the overall 
summary estimate was comparable to the primary analysis for corticosteroid use, although 
the results were not statistically significant (Table 2). The results were similar when 
restricting analysis to patients without inpatient hospitalization within 30 days prior to 
initiation of anti-TNF agents (Supplementary Table 3). The overall results were also 
comparable to the primary propensity-score matched analysis, when using inverse 
probability-of-treatment weight analysis (Supplementary Table 4).
 Comparative effectiveness and safety of certolizumab pegol vs. adalimumab
A total of 523 patients treated with CZP were propensity-score matched to 523 ADA-treated 
patients. The risks of all-cause hospitalization, CD-related hospitalization, abdominal 
surgery and new corticosteroid prescription were higher in CZP-treated patients as compared 
to ADA-treated patients (Figures 4A–E). On Cox proportional hazard analysis, after 
additional adjustment for variables not balanced through propensity score matching, we 
observed that the risk of all-cause hospitalization was statistically higher in CZP-treated 
patients compared to ADA-treated patients. The risks of CD-related hospitalization, 
abdominal surgery, corticosteroid prescription and serious infections were numerically 
higher in CZP-treated patients compared to ADA-treated patients, but these differences were 
not statistically significant. Persistence on index CZP was lower compared to index ADA, at 
both 6-months (CZP vs. ADA, 72% vs. 78%, p=0.04) and 12-months (56% vs. 43%, 
p<0.001).
The overall results were stable when the analysis was stratified by anti-TNF monotherapy or 
concomitant immunomodulator therapy (Supplementary Table 2), and on multiple sensitivity 
analyses (Table 2, Supplementary Table 3). The overall results were also comparable to the 
primary propensity-score matched analysis, when using inverse probability-of-treatment 
weight analysis (Supplementary Table 4).
 DISCUSSION
While anti-TNF-based therapy is the most effective treatment for CD, there are limited data 
on the comparative effectiveness and safety of different anti-TNF agents. In this nationally 
representative, propensity score-matched retrospective cohort study of 3,205 biologic-naïve 
patients with CD, we made several key observations. First, we observed that IFX-treated 
patients had lower risks of CD-related hospitalization, abdominal surgery and corticosteroid 
use compared to patients treated with ADA or CZP as the index anti-TNF agent. Second, 
patients started on IFX or ADA as the index anti-TNF agent were more likely to stay on 
their index agent at 6- and 12-months as compared to CZP-treated patients, even after 
adjusting for calendar year of prescription. Third, there was no significant difference in the 
risk of serious infections requiring hospitalization in IFX-, ADA- or CZP-treated patients. 
Based on the findings of our observational study, IFX may be superior to other anti-TNF 
agents for the treatment of CD. This is one of the largest observational comparative 
effectiveness studies in a contemporary cohort of biologic-naïve Crohn’s disease patients, 
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with patient-centered effectiveness and safety outcomes, assessed with robust 
complementary statistical approaches, with several stratified and/or sensitivity analyses.
These results were consistent on: (a) different statistical approaches including propensity 
score-matched analysis and inverse probability-of-treatment weighted analysis; (b) stratified 
analysis based on use of anti-TNF monotherapy or concomitant immunomodulator therapy; 
(c) sensitivity analysis after excluding patients without inpatient hospitalization in the 
preceding 30 days (to minimize misclassification of non-responders and confounding by 
disease severity); and (d) on restricting the analysis to patients with at least a 3-year baseline 
anti-TNF-free period (to minimize misclassification of anti-TNF-naivety).
Indirect treatment comparison network meta-analyses have suggested that in a subset of 
biologic-naïve patients with CD, IFX may be superior to CZP but comparable to ADA for 
induction of remission, but all agents are comparable for maintenance of remission.12, 13 
However, there are considerable differences in trial designs (no trials of standard IFX 
induction dosing, differences in design of maintenance trials, etc.) and co-interventions, with 
no head-to-head trials, all of which decrease the quality of evidence from these network 
meta-analyses. Moreover, all of these trials had restrictive inclusion criteria and were short-
term (maximum maintenance therapy, 1 year), and hence, not representative of real-world 
patient-relevant outcomes.
Our findings are consistent with, and expand upon, those of a recent retrospective cohort 
study, using the U.S. Medicare database. Osterman and colleagues found a lower risk of 
surgery in IFX-treated patients as compared to ADA-treated patients (5.5 vs. 6.9 surgeries 
per 100 person-years, respectively), although this difference was not statistically 
significant.14 In this Medicare population, approximately 45% patients were above 65 years 
of age. Among patients younger than 65 years, IFX use was associated with a lower risk of 
surgery compared to ADA use (adjusted odds ratio [OR], 0.66; 95% CI, 0.47–0.93). With a 
smaller sample size, the investigators also did not observe a statistically significant 
difference in risk of CD-related hospitalization, although the point estimate favored IFX 
(IFX vs. ADA: adjusted OR, 0.88; 95% CI, 0.72–1.07). Similar to our observation, the rate 
of persistence on index anti-TNF agent at 6 months was comparable for IFX and ADA in 
their cohort (49% vs. 47%); numerically, their overall persistence rates were lower compared 
to ours (78%), perhaps due to their older population who is at a higher risk of adverse 
events.
Despite all three anti-TNF agents having a similar mechanism of action, there are subtle 
differences in pharmacokinetics, which may explain these results. IFX, administered 
intravenously, is dosed based on body weight, whereas ADA- and CZP- have a fixed dose 
administered subcutaneously. In a retrospective cohort study, Bhalme et al observed 
differences in the rates of dose escalation due to therapeutic failure based on body mass 
index (BMI) in ADA-treated, but not IFX-treated, patients with CD.15 In an exploratory 
analysis of trials of ADA in patients with psoriasis, the response rate decreased progressively 
with increasing quartile of weight, from 74–79% in the lowest quartile to 62–71% in the 
highest quartile.16 In contrast, in a pooled analysis of 3 randomized controlled trials of IFX 
in psoriasis, the response rates were comparable in normal weight, overweight and obese 
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patients (78% vs. 78% vs. 74%, p=not significant). CZP, in contrast to both ADA and IFX, 
has a slightly different mechanism of action, and does not have complement-mediated or 
antibody-mediated cell-dependent cytotoxicity due to absence of IgG1-Fc portion.8 Hence, 
the clinical response to CZP may be different from ADA and IFX.
Our findings must be interpreted with caution, given the limitations associated with our 
study design. First, this was an observational, not an interventional study, and hence, there 
may be unmeasured confounders across groups. The potential for unmeasured confounding 
by severity is of particular importance, as administrative data do not include objective 
measures of disease severity such as endoscopic or biochemical markers; however, this is 
unlikely to significantly impact our findings, since anti-TNF agents are conventionally used 
for similar levels of disease activity. To the extent that IFX may preferentially be used 
among sicker patients, we may have underestimated the comparative benefits of IFX versus 
ADA or CZP. We also did not have data on baseline cigarette smoking status and weight, 
both of which can influence outcomes; however, there is no clear reason why tobacco use 
would be differential across exposure groups. Second, there is potential for misclassification 
of patients as anti-TNF-naïve, since the baseline period required that patients not have 
received another anti-TNF agent only 1 year prior to index date. It is well known that the 
response to a second anti-TNF agent is generally inferior to that of the first anti-TNF agent, 
and likewise, response decreases for the 3rd anti-TNF agent as compared to the second.17 We 
tried to minimize potential misclassification of biologic-naïve status by performing a 
sensitivity analysis increasing the baseline anti-TNF-free period to 3 years, and observed 
similar summary estimates for patient-relevant outcomes; however, we can not fully validate 
that patients were truly biologic-naïve. Third, both baseline covariates and outcomes were 
measured using administrative claims codes and may be subject to errors. Other prognostic 
factors influencing response to therapy such as disease duration, dose and frequency 
intensification, and effect of therapeutic drug monitoring could not be assessed. Fourth, we 
excluded patients with competing diagnoses for which anti-TNF agents may be used, such 
as spondyloarthropathy; however, with such an approach, we may have missed some patients 
with overlapping IBD and spondyloarthropathy who had been prescribed anti-TNF primarily 
for their bowel disease instead of their rheumatological condition.
In conclusion, using a propensity-matched retrospective observational cohort study, we 
observed that IFX may be superior to ADA and CZP for patient-relevant outcomes such as 
risk of hospitalization, surgery and need for corticosteroids, with comparable safety profile, 
in patients with CD. Future prospective cohort studies with adjustment for baseline objective 
measures of disease severity and pragmatic randomized controlled trials are warranted to 
confirm these observations.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flow of patients for identification of the anti-TNF-naive Crohn’s disease cohort.
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Figure 2. 
Survival free of (a) all-cause hospitalization, (b) Crohn’s disease-related hospitalization, (c) 
CD-related abdominal surgery, (d) corticosteroid prescription (at least 60 days after index 
anti-TNF agent) and (e) hospitalization for serious infection, in comparing propensity-score 
matched cohort of patients treated with infliximab (IFX) vs. adalimumab (ADA) as the first-
line index anti-TNF agent. IP refers to inpatient hospitalization.
Singh et al. Page 14
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Singh et al. Page 15
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Singh et al. Page 16
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Survival free of (a) all-cause hospitalization, (b) Crohn’s disease-related hospitalization, (c) 
CD-related abdominal surgery, (d) corticosteroid prescription (at least 60 days after index 
anti-TNF agent) and (e) hospitalization for serious infection, in comparing propensity-score 
matched cohort of patients treated with infliximab vs. certolizumab pegol as first-line index 
anti-TNF agent. IP refers to inpatient hospitalization.
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Figure 4. 
Survival free of (a) all-cause hospitalization, (b) Crohn’s disease-related hospitalization, (c) 
CD-related abdominal surgery, (d) corticosteroid prescription (at least 60 days after index 
anti-TNF agent) and (e) hospitalization for serious infection, in comparing propensity-score 
matched cohort of patients treated with certolizumab pegol vs. adalimumab as first-line 
index anti-TNF agent. IP refers to inpatient hospitalization.
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Table 1
Baseline demographic characteristics, healthcare utilization and IBD-related medication use in the 12 months 
prior to initiation of anti-TNF agents (figures in bold represent statistically significant difference between 
groups)
Variable Infliximab (n=1427) Adalimumab (n=1248) Certolizumab pegol (n=530)
p-value (for 
difference 
between 
groups)
Demographic variables
Mean age ± SD, years 41±15 40±14 41±14 0.39
Sex (% males) 46 44 46 0.85
Median follow-up after starting 
anti-TNF, months (IQR)
19 (10–35) 21 (11–38) 15 (8–27) <0.001
Healthcare utilization (in 12 months prior to starting anti-TNF)
Median outpatient visits (IQR) 8 (5–12) 8 (5–12) 8 (5–12) 0.64
Emergency room visits (% pts with 
≥1)
42 41 42 0.92
Inpatient visits (% pts with ≥1) 35 34 32 0.41
Imaging (% of pts with ≥1) 46 48 53 0.02
Endoscopic procedures (% pts 
with ≥1)
60 60 67 0.01
Prior abdominal surgery (% pts 
with ≥1)
4 5 7 0.006
Perianal CD* (%) 12.6 12.7 13.2 0.94
Median generic medication count 
(IQR)
6 (4–8) 6 (4–9) 6 (4–9) 0.39
IBD-related medication use (in 12 months prior to starting anti-TNF)
Mesalamine, oral, % 52 49 49 0.41
Steroids
• Any prior use, %
• Recent (in 90 days prior to anti-
TNF), %
65
50
71
52
72
56
<0.001
0.07
Immunomodulators
• Any prior use, %
• Concurrent (index date ± 30 
days), %
45
32
44
26
43
26
0.51
0.004
Narcotics, % 49 51 52 0.22
*based on ICD-9 codes, 565.x and 566.x
Abbreviations: IQR-interquartile range, n-number of patients, pts-patients, SD-standard deviation, TNF-tumor necrosis factor
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